Whitehawk Therapeutics
WHWK
73 hedge funds and large institutions have $75.3M invested in Whitehawk Therapeutics in 2023 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 25 increasing their positions, 15 reducing their positions, and 6 closing their positions.
1,750% more call options, than puts
Call options by funds: $74K | Put options by funds: $4K
100% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 6
67% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 15
9% more funds holding
Funds holding: 67 → 73 (+6)
1.55% more ownership
Funds ownership: 58.51% → 60.06% (+1.5%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
25% less capital invested
Capital invested by funds: $101M → $75.3M (-$25.5M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$1.45M |
| 2 |
ECM
ExodusPoint Capital Management
New York
|
+$995K |
| 3 |
Morgan Stanley
New York
|
+$706K |
| 4 |
Renaissance Technologies
New York
|
+$243K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$199K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AAA
Affinity Asset Advisors
New York
|
-$1.28M |
| 2 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$188K |
| 3 |
Goldman Sachs
New York
|
-$172K |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
-$136K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$132K |
WHWK Hedge Fund Activity: Q3 2023 in Review
73 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Whitehawk Therapeutics (WHWK) for Q3 2023, worth a combined $75.3M — down 25% from $101M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new WHWK positions and 6 closed out — a net gain of 6 holders — while 25 added to existing stakes and 15 trimmed.
The largest buyer was Janus Henderson Group, adding an estimated $1.45M. The largest seller was Affinity Asset Advisors, exiting entirely with an estimated $1.28M sold.
- 73 institutional investors held Whitehawk Therapeutics (WHWK) as of Q3 2023, up from 67 in Q2 2023.
- Funds reported $75.3M of Whitehawk Therapeutics stock for Q3 2023, down 25% quarter-over-quarter.
- 12 funds opened new Whitehawk Therapeutics positions in Q3 2023 and 6 closed out, a net change of +6 holders.
- The largest Whitehawk Therapeutics buyer in Q3 2023 was Janus Henderson Group, an estimated $1.45M added.
- The largest Whitehawk Therapeutics seller in Q3 2023 was Affinity Asset Advisors, an estimated $1.28M sold.
Based on aggregated 13F filings for Q3 2023.